Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04112381 · ClinicalTrials.gov registry record · NA
Bilateral Treatment of Medication Refractory Essential Tremor
A NA study of Essential Tremor, sponsored by InSightec.
- Active
- Registry status
- NA
- Development phase
- 51
- Enrollment target
- 7
- Study locations
NCT04112381: Active NA study of Essential Tremor, sponsored by InSightec.
NCT04112381 is a NA study of Essential Tremor that is active but no longer recruiting, run by InSightec. The registered enrollment target is 51 participants, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (87% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04112381, a NA study of Essential Tremor, is active but no longer recruiting, sponsored by InSightec.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.
Primary Outcome
rate of adverse events following the Exablate secondary procedure
Conditions Studied
Interventions
- DEVICE Exablate Model 4000 Type 1.0/1.1
Study Locations (7)
California
- Stanford University, School of Medicine - Stanford
Maryland
- University of Maryland - Baltimore
New York
- Weill Cornell Medicine - New York
Ohio
- The Ohio State University - Wexner Medical Center - Columbus
Pennsylvania
- University of Pennsylvania - Philadelphia
Virginia
- University of Virginia - Charlottesville
West Virginia
- West Virginia University - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2026-06 |
| Phase | NA |
What the registry record for NCT04112381 still lists
NCT04112381 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 401-participant average among 41 other Essential Tremor trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Essential Tremor appearing as the primary indexed condition, and to 1 intervention - of which Exablate Model 4000 Type 1.0/1.1 is the first listed.
NCT04112381 lists 7 locations in 7 states (California, Maryland, New York).
Frequently Asked Questions
What is clinical trial NCT04112381 about?
NCT04112381 is a clinical study titled "Bilateral Treatment of Medication Refractory Essential Tremor". The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.
What is the current status of trial NCT04112381?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 51 participants. The study started on 2020-06-30. Estimated completion is 2026-06.
What conditions does trial NCT04112381 study?
This clinical trial studies the following conditions: Essential Tremor.
What interventions are being tested in trial NCT04112381?
The interventions under investigation include: Exablate Model 4000 Type 1.0/1.1 (DEVICE).
Who is sponsoring clinical trial NCT04112381?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04112381 being conducted?
This trial has 7 study locations across California, Maryland, New York, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Essential Tremor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04112381's enrollment target sits among peer trials
51 25th of 41 higher than 17 of 41 other Essential Tremor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Essential Tremor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Circadian Adaptive DBS in Essential Tremor
RECRUITING · NA
-
Motor Network Physiology
RECRUITING · NA
-
Investigating Subcortical Contributions to Speech Sequencing in Deep Brain Stimulator Recipients
RECRUITING · NA
-
3-D Tractography FUS Ablation for Essential Tremor
RECRUITING · NA
-
Directional Versus Nondirectional DBS for ET
RECRUITING · NA
-
Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI